J. Kelly Ganjei is the CEO and President of AmplifyBio, LLC, a contract research organization focused on helping advanced therapy clients navigate the concept to commercial journey. Mr. Ganjei was brought in to lead the spin-out of AmplifyBio from Battelle in mid-2021.
Before AmplifyBio, Mr. Ganjei was the Chief Executive Officer and Chairman of the Board of Cognate BioServices, a CDMO focused on the cell and gene therapy fields. Mr. Ganjei has nearly 30 years of experience within the advanced therapy business, venture capital, and IT sectors.
Previously, Mr. Ganjei was involved in many start-up companies with leadership roles, including but not limited to, Remegenix, TissueGene, LabVantage, and Biognosis. In these roles, he was responsible for spearheading the commercialization of innovative approaches to treating traumatic brain injury and Alzheimer’s disease, an allogenic cell-mediated gene therapy with complex development and regulatory pathways and developing the global informatics infrastructure for the company and its affiliates. Mr. Ganjei started his career working under Ron Schwartz, Luciano D’Adamio, and others in the Lab of Cellular and Molecular Immunology at the NIAID within the NIH.
Mr. Ganjei has published numerous scientific, peer-reviewed papers and has been a guest speaker and presenter at various business forums. Mr. Ganjei received his B.S. in Microbiology from the University of Maryland College Park in 1995. Mr. Ganjei has significant biotechnology operational experience and pre-clinical, clinical, and commercial drug development and manufacturing knowledge.